Wutah dodolan YoY sajrone 12 wulan kepungkur: cgen.com (CGEN)

Compugen Ltd. is a recognized expert in identifying targets for cancer immunotherapy. An AI platform ensures high development efficiency, while revenue is based on strategic licensing agreements. The year-over-year sales trajectory over the trailing four quarters demonstrates revenue dynamics, where 995.50 expresses the latest metric level, allowing for an assessment of the business expansion rate.

For a fundamental valuation of Compugen Ltd. (CGEN), it is critical to track revenue dynamics, which currently stand at 995.50. By analyzing the TTM sales growth rate, an investor can discern the business expansion pace over a rolling year, which, for a biotech sector company with an AI model, reflects the monetization efficiency of licensing agreements with pharma behemoths and the resilience of demand for innovative developments.